Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.

Autores:: Yepes Barreto, Ismael de Jesús
Osorio Marín, Claudia
Múnera Contreras, María Nicol

Tipo de recurso:: Article of journal

Fecha de publicación:: 2016

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_90af175a682a70a132c23172d8ba5462
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13042
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
dc.title.translated.eng.fl_str_mv	Efficacy and determining factors of the response to treatment with clarithromycin, esomeprazol and amoxacylin for H. Pylori infection.
title	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
spellingShingle	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori. Infección por Helicobacter Gastroenterología Endoscopia del sistema digestivo Helicobacter infections Gastroenterology Endoscopy digestive system
title_short	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
title_full	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
title_fullStr	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
title_full_unstemmed	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
title_sort	Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.
dc.creator.fl_str_mv	Yepes Barreto, Ismael de Jesús Osorio Marín, Claudia Múnera Contreras, María Nicol
dc.contributor.author.spa.fl_str_mv	Yepes Barreto, Ismael de Jesús Osorio Marín, Claudia Múnera Contreras, María Nicol
dc.subject.spa.fl_str_mv	Infección por Helicobacter Gastroenterología Endoscopia del sistema digestivo
topic	Infección por Helicobacter Gastroenterología Endoscopia del sistema digestivo Helicobacter infections Gastroenterology Endoscopy digestive system
dc.subject.eng.fl_str_mv	Helicobacter infections Gastroenterology Endoscopy digestive system
publishDate	2016
dc.date.accessioned.none.fl_str_mv	2016-07-15 00:00:00
dc.date.available.none.fl_str_mv	2016-07-15 00:00:00
dc.date.issued.none.fl_str_mv	2016-07-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2016-2854
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2016-2854
identifier_str_mv	2215-7840 10.32997/rcb-2016-2854 2389-7252
url	https://doi.org/10.32997/rcb-2016-2854
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2854/2397
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2016
dc.relation.citationendpage.none.fl_str_mv	264
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	258
dc.relation.citationvolume.spa.fl_str_mv	7
dc.relation.references.spa.fl_str_mv	Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van-der-Merwe S, Vaz-Coelho LG, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011; 20(3): 299-304. Martinez JD, Henao S, Lizarazo JI. Resistencia antibiótica del Helicobacter pylori en América Latina y el Caribe. Rev Col Gastroenterol. 2014; 29(3): 217-26. Bravo LE, Cortes A, Carrascal E, Jaramillo R, García LS, Bravo PE. et al. Helicobacter pylori: patología y prevalencia en biopsias gástricas en Colombia. Colombia médica. 2003; 34(3): 124-31. De-Armas-Daza L. Prevalencia de Helicobacter pylori según el resultado de la prueba de ureasa rápida y su asociación con alteraciones de la mucosa gástrica en pacientes que asistieron a realizarse endoscopia en cuatro consultorios médicos de Valledupar durante el año 2007: Universidad Nacional de Colombia; 2011. http://www.bdigital.unal.edu.co/7012/1/597673.2011.pdf Otero W, Otero LP, Vallejo MT, Torres-Amaya M, Pardo R, Sabbagh L. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015; 30: 45-52. Camargo MC, Garcia A, Riquelme A, Otero W, Camargo CA, Hernández-García T, Candia R, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014; 109(4): 485-95. https://doi.org/10.1038/ajg.2014.24 Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002; 53(2): 163-71. https://doi.org/10.1046/j.0306-5251.2001.01531.x Zullo A, De-Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks. J Clin Gastroenterol. 2012; 46(4): 259-61. https://doi.org/10.1097/MCG.0b013e318247177e Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2015; 42(2): 131-41. https://doi.org/10.1111/apt.13259 Bago J, Galovic A, Belosic Halle Z, Bilic A, Bevanda M, Bago P. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr. 2004; 116(14): 495-99. https://doi.org/10.1007/BF03040946 Asaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, Fujioka T, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001; 6(3): 254-61. https://doi.org/10.1046/j.1523-5378.2001.00037.x Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998; 12(4): 383-8. https://doi.org/10.1046/j.1365-2036.1998.00315.x Hassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther. 2003; 18(6): 641-6. https://doi.org/10.1046/j.1365-2036.2003.01694.x Ellenrieder V, Fensterer H, Waurick M, Adler G, Glasbrenner B. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998; 12(7): 613-8. https://doi.org/10.1046/j.1365-2036.1998.00354.x Choi IJ, Jung HC, Choi KW, Kim JH, Ahn DS, Yang US, Rew JS, et al. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002; 16(1): 145-51. https://doi.org/10.1046/j.1365-2036.2002.01130.x Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102(8): 1808-25. https://doi.org/10.1111/j.1572-0241.2007.01393.x Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5): 646-64. https://doi.org/10.1136/gutjnl-2012-302084 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014; 20(40): 14973-85. https://doi.org/10.3748/wjg.v20.i40.14973 Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2004; 18(4): CD003840. https://doi.org/10.1002/14651858.CD003840.pub2 Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010; 8(2): 105-10. https://doi.org/10.1016/j.cgh.2009.07.017 Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012; 104(6): 488-92. https://doi.org/10.1093/jnci/djs003 Bravo LE, Garcia LS, Collazos PA. Cancer survival in Cali, Colombia: A population-based study, 1995-2004. Colomb Med. 2014; 45(3): 110-16. https://doi.org/10.25100/cm.v45i3.1525 Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E, La Vecchia C. Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol. 2014; 25(9): 1843-53. https://doi.org/10.1093/annonc/mdu206 Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8(4): 6530-43. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006; 119(3): 217-24. https://doi.org/10.1016/j.amjmed.2005.10.003 Isaza C, Henao J, Martínez JH, Sepulveda Arias JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007; 7:6. https://doi.org/10.1186/1472-6904-7-6 Bravo-Villalta HV, Yamamoto K, Nakamura K, Baya A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol. 2005; 61(3): 179-84. https://doi.org/10.1007/s00228-004-0890-5 Megraud F, Coenen S, Versporten A, Kist M, López-Brea M, Hirschl AM, Andersen LP, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62(1): 34-42. https://doi.org/10.1136/gutjnl-2012-302254 Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol. 2011; 49(10): 3638-43. https://doi.org/10.1128/JCM.01067-11
dc.rights.spa.fl_str_mv	Revista Ciencias Biomédicas - 2016
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Revista Ciencias Biomédicas - 2016 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2854
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/ae5b7d78-576a-4a59-a1fc-98ca17aca07b/download
bitstream.checksum.fl_str_mv	1f27d8f236648534a6f0ae1a6cf009c7
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814213997559283712
spelling	Yepes Barreto, Ismael de JesúsOsorio Marín, ClaudiaMúnera Contreras, María Nicol2016-07-15 00:00:002016-07-15 00:00:002016-07-152215-784010.32997/rcb-2016-28542389-7252https://doi.org/10.32997/rcb-2016-2854application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2854/2397Núm. 2 , Año 201626422587Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van-der-Merwe S, Vaz-Coelho LG, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011; 20(3): 299-304.Martinez JD, Henao S, Lizarazo JI. Resistencia antibiótica del Helicobacter pylori en América Latina y el Caribe. Rev Col Gastroenterol. 2014; 29(3): 217-26.Bravo LE, Cortes A, Carrascal E, Jaramillo R, García LS, Bravo PE. et al. Helicobacter pylori: patología y prevalencia en biopsias gástricas en Colombia. Colombia médica. 2003; 34(3): 124-31.De-Armas-Daza L. Prevalencia de Helicobacter pylori según el resultado de la prueba de ureasa rápida y su asociación con alteraciones de la mucosa gástrica en pacientes que asistieron a realizarse endoscopia en cuatro consultorios médicos de Valledupar durante el año 2007: Universidad Nacional de Colombia; 2011. http://www.bdigital.unal.edu.co/7012/1/597673.2011.pdfOtero W, Otero LP, Vallejo MT, Torres-Amaya M, Pardo R, Sabbagh L. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015; 30: 45-52.Camargo MC, Garcia A, Riquelme A, Otero W, Camargo CA, Hernández-García T, Candia R, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014; 109(4): 485-95. https://doi.org/10.1038/ajg.2014.24Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002; 53(2): 163-71. https://doi.org/10.1046/j.0306-5251.2001.01531.xZullo A, De-Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks. J Clin Gastroenterol. 2012; 46(4): 259-61. https://doi.org/10.1097/MCG.0b013e318247177eHarb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2015; 42(2): 131-41. https://doi.org/10.1111/apt.13259Bago J, Galovic A, Belosic Halle Z, Bilic A, Bevanda M, Bago P. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr. 2004; 116(14): 495-99. https://doi.org/10.1007/BF03040946Asaka M, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, Fujioka T, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001; 6(3): 254-61. https://doi.org/10.1046/j.1523-5378.2001.00037.xBigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998; 12(4): 383-8. https://doi.org/10.1046/j.1365-2036.1998.00315.xHassan C, De Francesco V, Zullo A, Scaccianoce G, Piglionica D, Ierardi E, Panella C, et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther. 2003; 18(6): 641-6. https://doi.org/10.1046/j.1365-2036.2003.01694.xEllenrieder V, Fensterer H, Waurick M, Adler G, Glasbrenner B. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998; 12(7): 613-8. https://doi.org/10.1046/j.1365-2036.1998.00354.xChoi IJ, Jung HC, Choi KW, Kim JH, Ahn DS, Yang US, Rew JS, et al. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002; 16(1): 145-51. https://doi.org/10.1046/j.1365-2036.2002.01130.xChey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102(8): 1808-25. https://doi.org/10.1111/j.1572-0241.2007.01393.xMalfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5): 646-64. https://doi.org/10.1136/gutjnl-2012-302084Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014; 20(40): 14973-85. https://doi.org/10.3748/wjg.v20.i40.14973Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2004; 18(4): CD003840. https://doi.org/10.1002/14651858.CD003840.pub2Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010; 8(2): 105-10. https://doi.org/10.1016/j.cgh.2009.07.017Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012; 104(6): 488-92. https://doi.org/10.1093/jnci/djs003Bravo LE, Garcia LS, Collazos PA. Cancer survival in Cali, Colombia: A population-based study, 1995-2004. Colomb Med. 2014; 45(3): 110-16. https://doi.org/10.25100/cm.v45i3.1525Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E, La Vecchia C. Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol. 2014; 25(9): 1843-53. https://doi.org/10.1093/annonc/mdu206Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8(4): 6530-43.Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006; 119(3): 217-24. https://doi.org/10.1016/j.amjmed.2005.10.003Isaza C, Henao J, Martínez JH, Sepulveda Arias JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007; 7:6. https://doi.org/10.1186/1472-6904-7-6Bravo-Villalta HV, Yamamoto K, Nakamura K, Baya A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol. 2005; 61(3): 179-84. https://doi.org/10.1007/s00228-004-0890-5Megraud F, Coenen S, Versporten A, Kist M, López-Brea M, Hirschl AM, Andersen LP, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013; 62(1): 34-42. https://doi.org/10.1136/gutjnl-2012-302254Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol. 2011; 49(10): 3638-43. https://doi.org/10.1128/JCM.01067-11Revista Ciencias Biomédicas - 2016https://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2854Infección por HelicobacterGastroenterologíaEndoscopia del sistema digestivoHelicobacter infectionsGastroenterologyEndoscopy digestive systemEficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.Efficacy and determining factors of the response to treatment with clarithromycin, esomeprazol and amoxacylin for H. Pylori infection.Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2662https://repositorio.unicartagena.edu.co/bitstreams/ae5b7d78-576a-4a59-a1fc-98ca17aca07b/download1f27d8f236648534a6f0ae1a6cf009c7MD5111227/13042oai:repositorio.unicartagena.edu.co:11227/130422024-09-05 15:30:24.987https://creativecommons.org/licenses/by-nc-sa/4.0/Revista Ciencias Biomédicas - 2016metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Eficacia y factores determinantes de la respuesta al tratamiento con claritromicina, esomeprazol y amoxacilina para la infección por H. Pylori.

Publicaciones similares